Information  X 
Enter a valid email address

Xenova Group plc (XEN)

  Print      Mail a friend

Thursday 24 June, 2004

Xenova Group plc

Xenova to Host R&D Days

Xenova Group plc

Xenova to Host R&D Days
in New York and London


Slough, UK, 24 June 2004 - Xenova Group plc (London Stock Exchange:
XEN; NASDAQ: XNVA) will next week host an Investor/Analyst R&D Day in
both New York and London.   The event in New York will be held at
08:30 a.m. EDT on Tuesday 29 June and the London event will take
place at 08:30 a.m. BST on Friday 2 July.  The New York R&D Day will
be webcast and can be accessed by going to the Company website at
www.xenova.co.uk.
Xenova's senior management and senior scientific staff will discuss
the Company's clinical development programmes, with a focus on
TransMID(TM), the Company's candidate for treatment of Glioblastoma
Multiforme, and will also include presentations on TA-CD and TA-NIC,
the Company's addiction vaccines, the Novel DNA Targeting Agents, and
XR303, a candidate for the treatment of pancreatic cancer.

To attend the event in New York, please contact Lee Stern at The
Trout Group at 212-477-9007 x22.  For the London event, contact Mo
Noonan at Financial Dynamics at 020 7831 3113.

Contacts:

XenovaGroup plc                      +44 (0)1753 706600
David A. Oxlade, Chief Executive Officer
Daniel Abrams, Finance Director
Veronica Cefis Sellar, Head of Corporate Communication

UK - Financial Dynamics          +44 (0)20 7831 3113
David Yates
Ben Atwell

US - Trout Group/BMC Communications
                                                   +1 212 477 9007
Media:              Brad Miles
Investors:        Lee Stern

Xenova Group plc is a UK-based biopharmaceutical company focused on
the development of novel drugs to treat cancer and addiction with a
secondary focus in immunotherapy.  The Company has a broad pipeline
of products in clinical development, including three cancer
programmes:  its lead product TransMID(TM), for the treatment of
high-grade glioma, is in Phase III trials, and its novel DNA
targeting agents and XR303 are both in Phase I for cancer
indications.  Xenova is also developing two therapeutic vaccines for
cocaine and nicotine addiction, which are in Phase II and Phase I
trials respectively.  Quoted on the London Stock Exchange (XEN) and
on NASDAQ (XNVA), Xenova employs approximately 112 people throughout
its sites in the UK and North America. (Reuters XEN.L; Bloomberg XEN
LN)
For further information about Xenova and its products please visit
the Xenova website at www.xenova.co.uk.
                 ___________________________________

Disclaimer to take advantage of the "Safe Harbor" provisions of the
US Private Securities Litigation Reform Act of 1995. This press
release contains "forward-looking statements," including statements
about our ability to commercialize products. Various risks may cause
Xenova's actual results to differ materially from those expressed or
implied by the forward looking statements, including: unexpected
costs; commercial limitations imposed by patents owned or controlled
by third parties; our dependence upon strategic alliance partners to
develop and commercialize products and services; difficulties or
delays in obtaining regulatory approvals to market products and
services resulting from our development efforts; the requirement for
substantial funding to conduct research and development and to expand
commercialization activities; and product initiatives by
competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the
Securities and Exchange Commission.  We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.


---END OF MESSAGE--